Today (30th) morning, the National Health and Wellness Commission held a press conference. Wang Linhong, chairman of the Women’s Health Branch of the Chinese Preventive Medical Association and chief expert of chronic diseases in China CDC, said that at present, five HPV vaccine products in China have been approved for registration, including three imported HPV vaccines and two domestic HPV vaccines. According to the national routine immunization report data, from 2018 to 2020, the number of HPV vaccination increased year by year, from 3.417 million doses in 2018 to 12.279 million doses in 2020. However, on the whole, the current supply of HPV vaccine is still in short supply, and the HPV vaccination rate of school-age women is at a low level.

　　Recently, the country has been actively strengthening the scientific propaganda of HPV vaccination and promoting the pilot work of HPV vaccination. In accordance with the working idea of overall promotion and key breakthrough, Guangdong, Hainan and Fujian provinces have successively started to implement the work of free vaccination of domestic bivalent HPV vaccine for school-age girls in the province, which will be included in the practical project of the provincial party Committee and provincial government for the people in 2022. Many cities use the platform of healthy cities to promote the pilot work of comprehensive prevention and control of cervical cancer. Jinan, Xiamen, Wuxi, Erdos and other pilot cities have introduced the policy of free HPV vaccination for school-age girls, and Chengdu has given a fixed subsidy for HPV vaccination for school-age girls, which can meet the different needs of clients for HPV vaccine. According to the recent summary data, the coverage rate of HPV vaccine for junior high school girls in these areas has been greatly improved, and some cities have exceeded 90%.

　　In the next step, we will vigorously sum up and promote the experience of piloting and promoting the free HPV vaccination policy to cover more people. At the same time, increase multi-sectoral cooperation, gradually solve the problems such as insufficient supply of HPV vaccine, and strive to meet the vaccination demand. Here, I would also like to make a popular science for the majority of female friends. At present, there are bivalent, tetravalent and nonavalent HPV vaccines that can be applied in China, and the age range used is 9-mdash; 45-year-old female. The high-risk types of HPV causing cervical cancer are mainly subtypes 16 and 18, so bivalent HPV vaccine can prevent about 70% of cervical cancer. Another important point is that HPV vaccine has the best protection effect for young women who have not been infected with HPV virus. WHO recommends 9— 14-year-old girls are the primary population for HPV vaccination. The earlier they are vaccinated, the better the effect will be. In the current tight supply of vaccines, don’t miss the best vaccination time by waiting for a higher-priced vaccine.

　　(CCTV reporter Shi Yingchun and Du Xinzhu)